| Document |
Document Title |
|
WO/2015/104433A1 |
The invention relates to benzo[c][1,2,5]oxadiazole derivatives, and the use thereof as antibiotics and in particular for the treatment and/or prevention of diseases caused by bacteria, in particular of diseases caused by Helicobacter.
|
|
WO/2015/092740A1 |
The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions compri...
|
|
WO/2015/091463A1 |
A compound of Formula (1) wherein R1 represents hydrogen, halo, a C1-C4 alkyl group, a C1-C4 alkylhalide group, a C1-C4 alkoxy-C2-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group or a C3- C7 cyclo alkyl group; R2 represents F...
|
|
WO/2015/078802A1 |
The present invention relates to compounds of general formula (I), wherein the groups R1, R2, R3, X, m and n are defined as in claim 1, wich have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate ...
|
|
WO/2015/073140A1 |
The present invention relates to 1,3,4-alkenyl oxadiazole amino acid derivatives of formulae I and II, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosin...
|
|
WO/2015/070007A1 |
The present application is directed to processes and intermediates for making 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluoro
phenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide, which is an inhibitor of indoleamine 2,3-di...
|
|
WO/2015/044170A1 |
The invention relates to substituted phenylalanine derivatives of formula (I), in which R1 stands for a group of formula (II) or formula (III), R2 stands for hydrogen, fluorine, chlorine, methyl, or methoxy, R3 stands for hydrogen, fluor...
|
|
WO/2015/044167A1 |
The invention relates to substituted phenylalanine derivatives and to methods for the production thereof, in addition to the use of said derivatives for producing medicaments for the treatment and/or prophylaxis of diseases, in particula...
|
|
WO/2015/033301A1 |
The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeut...
|
|
WO/2015/033299A1 |
The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeuti...
|
|
WO/2015/022038A1 |
Compounds of formula (I) in which R, W, R1, R4, X1, X2, X3, X4 and q have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovasc...
|
|
WO/2015/002230A1 |
The present invention relates to compounds (I), which have RORγt inhibitory effects, and salts thereof. In formula (I), each notation is as described in the Specification. (I)
|
|
WO/2014/202510A1 |
The invention relates to aryl sulfide derivatives and aryl sulfoxide derivatives, use thereof as acaricides and insecticides for controlling animal pests, and methods and intermediate products for the production thereof. The aryl sulfide...
|
|
WO/2014/202827A1 |
Compounds of formula (I), wherein R1 to R8 A, B, Z1 and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists...
|
|
WO/2014/201172A1 |
Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of G...
|
|
WO/2014/184058A1 |
The present invention relates to substituted 1,2,5-oxadiazole compounds of the formula (I) and the N-oxides and salts thereof and to compositions comprising the same. The invention also relates to the use of the 1,2,5-oxadiazole compound...
|
|
WO/2014/181788A1 |
The present invention provides: a novel α-substituted glycineamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the α-substituted glycineamide derivative or a pharmacologically acce...
|
|
WO/2014/178381A1 |
Provided is a new compound having glycogen synthase activation potency, but minimal activation of receptor PPAR, and a high degree of safety. A compound represented by general formula [I], or a pharmaceutically acceptable salt thereof....
|
|
WO/2014/173904A1 |
The present invention relates to compounds of formula (I) and their uses. In particular, though not exclusively, it concerns heterocyclic compounds that inhibit the biogenesis of adhesive pili in Gram- negative bacteria, and their use in...
|
|
WO/2014/175136A1 |
The objective of the present invention is to provide: an optical film which is substantially capable of providing λ/4 retardation, while being suppressed in changes in the optical performance due to humidity changes, and which also has ...
|
|
WO/2014/172044A1 |
The present invention relates to compounds of Formula (I), wherein the variables are as defined herein. Pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceut...
|
|
WO/2014/165090A1 |
Disclosed are compounds that can be used for treating tuberculosis.
|
|
WO/2014/161516A1 |
A substituted diazole of genera l formula (1) wherein X is 0 or S; R is selected from the group consisting of: H, NH2-, C1-C11n alkyl, cyclohexyl-, benzyl-, phenyl-, pyridyl- or phenyl- substituted, in positions 2, 3, 4 or 5, by one or m...
|
|
WO/2014/154726A1 |
The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors ...
|
|
WO/2014/154727A1 |
The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors ...
|
|
WO/2014/135423A1 |
The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of...
|
|
WO/2014/129796A1 |
The present invention relates to novel compounds of Formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used for the treatment of autoimmune diseases, a method for preparing the same, and a pharmaceutical comp...
|
|
WO/2014/126972A1 |
The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, wherein X is defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therap...
|
|
WO/2014/123203A1 |
Provided is a compound having PTP-1B inhibitory activity that is excellent as a drug, or a pharmaceutically acceptable salt thereof. A compound represented by general formula (I) (in the formula, each symbol means the same as in the spec...
|
|
WO/2014/079850A1 |
The present invention relates to compounds of general formula (I-1) or (I-2) wherein R1 is hydrogen, lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; R1' is hydrogen, lower alkyl, lower alko...
|
|
WO/2014/078208A1 |
The present invention relates to aryl oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2014/078197A1 |
The present invention relates to novel 2-thio-l,3,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-l-phosphate receptors.
|
|
WO/2014/078209A1 |
The present invention relates to aryl oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1 -phosphate receptors.
|
|
WO/2014/071342A1 |
The present invention relates to substituted 1,3,4-oxadiazoles-2-thio derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate recept...
|
|
WO/2014/065215A1 |
The present invention addresses the problem of providing: a transparent electrode provided with conductivity and light transmissivity, having low sheet resistance, and exhibiting excellent durability; and an electronic device and an orga...
|
|
WO/2014/063199A1 |
Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in...
|
|
WO/2014/061693A1 |
The purpose of the present invention is to provide a novel compound that has an ACC2 inhibitory activity. Also provided is a medicinal composition containing the compound. A compound represented by formula (I) or a pharmaceutically accep...
|
|
WO/2014/055916A1 |
The present invention relates to substituted aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2014/055911A1 |
The present invention relates to bicyclic aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2014/054053A1 |
The present disclosure relates to a series of spirocyclic compounds of formula (I), their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates, hydrates, N-Oxides, Co crystals and formulations there...
|
|
WO/2014/049107A1 |
The present invention concerns compounds of general formula (I): (I) in which Y and Z are chosen from CH and N; T is chosen from CO or SO2; n is 1 to 3; R1 represents a group chosen, for example, from C1-C3 alkyl chains unsubstituted or ...
|
|
WO/2014/037342A1 |
The invention relates to bicycloaryl carboxylic acid amides of general formula (I), used as herbicides. In said formula (I), X and W represent groups such as hydrogen, organic groups such as alkyl, and other groups such as halogen. Q rep...
|
|
WO/2014/031755A1 |
Disclosed herein are novel derivatives of fendiline, including compounds of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising these derivativ...
|
|
WO/2014/026244A1 |
The present invention relates to photoactive optoelectronic devices, such as organic photovoltaic devices, and transistor devices, and to organic compounds for use in the optoelectronic and transistor devices. The present invention also ...
|
|
WO/2014/018569A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-γ- lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other com...
|
|
WO/2014/005968A1 |
The invention relates to a compound of formula (I), wherein i.a. A1is -CH2- or -C(O)-; one of R1 and R2 is hydrogen and the other one is -A2 -C(O)-R3; A2 is NH- or absent; and R3 is (A), (B) or (C) The compounds are preferential agonists...
|
|
WO/2014/003124A1 |
The compound represented by formula (1) or a salt thereof has a collagen production-inhibiting effect, and is thus useful for use in the prevention, treatment, or the like of diseases associated with overproduction of collagen such as pu...
|
|
WO/2013/182046A1 |
An organic electronic material having the structure of formula (I) or (II) as described below and an organic electroluminescent device are disclosed. The organic electroluminescent device possesses high electronic transmission and inject...
|
|
WO/2013/181840A1 |
The present invention relates to a heterocyclic group contained amino-methanol derivative, and salt, a synthetic method and use thereof, and belongs to the medical field. The heterocyclic group contained amino-methanol derivative and the...
|
|
WO/2013/181332A1 |
In one aspect, the invention relates to compounds having the formula: (I) where R1, R2, R3, R7, R8, Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donor...
|
